Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds
People with non-cystic fibrosis (CF) bronchiectasis are at an increased risk for anxiety and depression, and this risk is associated with...
VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE
Vertex Pharmaceuticals announced the completion of its Phase III trial of Trikafta in children ages 6 through 11 years with cystic...
A case for improved carrier screening
Expanded carrier screening addresses limitations in historical ethnic-based screenings, including potential racial and ethnic bias....
Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is safe for use in children with cystic fibrosis (CF) as young as age 6, data...
Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS
The European Commission and European Medicines Agency have approved the triple combination Kaftrio for use in certain cystic fibrosis...
Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis
Age may influence outcomes in lung transplant recipients with cystic fibrosis (CF), according to study results published in the Annals of...
CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics
ContraFect will receive funding from the Cystic Fibrosis Foundation to conduct preclinical research about the potential of direct lytic...
